What Is Geographic Atrophy and How Can Valeda Help?
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (dry AMD)—a progressive condition that causes the gradual loss of retinal cells responsible for central vision. GA is one of the leading causes of irreversible central vision loss in older adults. But with earlier detection, advanced imaging, and emerging treatments such as photobiomodulation (PBM) with the Lumithera Valeda system, patients now have more support options than ever.
At Peter Ivins Eye Care in Bearsden, Scotland, geographic atrophy management is a core area of clinical excellence. With Scotland’s first Valeda PBM clinic, cutting-edge ZEISS retinal imaging, and leadership from international key opinion leader Craig McArthur, the practice offers one of the most advanced AMD care pathways in the UK.
This in‑depth article explains:
- What geographic atrophy is
- What causes it and how it progresses
- How symptoms develop
- How GA is diagnosed using world‑class imaging technology
- How Valeda PBM may help support retinal health
Why Peter Ivins Eye Care is uniquely positioned to manage GA
What Is Geographic Atrophy?
Geographic atrophy is a late stage of dry AMD. It occurs when patches of the retinal pigment epithelium (RPE) and overlying photoreceptors progressively deteriorate, creating well‑defined areas of atrophy. These areas expand over time, leading to increasingly noticeable gaps in central vision.
Key characteristics of geographic atrophy:
- Loss of RPE cells that support photoreceptors
- Thinning of the retina in affected areas
- Well‑demarcated patches (areas of atrophy)
- Gradual enlargement of these patches over months to years
- Progressive decline in central or para‑central vision
GA does not involve bleeding or fluid (unlike wet AMD), but it still leads to significant visual disability.
Symptoms of Geographic Atrophy
Symptoms vary based on the size and location of the atrophic patches.
Common symptoms include:
- Missing or blank spots in central or near‑central vision
- Difficulty recognising faces
- Reduced contrast sensitivity
- Trouble reading, even with good lighting
- Faded or washed‑out colours
- Slow dark adaptation (difficulty adjusting to low light)
In early GA, patients may not notice symptoms until an atrophic patch encroaches on the central retina.
How Geographic Atrophy Progresses
GA is typically slow but relentless. Atrophic lesions expand at an average of 1.2–2.0 mm² per year, although rates vary between individuals.
Progression is influenced by:
- Genetics
- Smoking history
- Macular pigment levels
- Drusen load and type
- Inflammatory and oxidative stress factors
Monitoring growth with precision imaging is essential for understanding risk and adjusting management.
How Geographic Atrophy Is Diagnosed at Peter Ivins Eye Care
Few clinics in the UK offer a diagnostic suite as advanced and integrated as Peter Ivins Eye Care. Early and accurate detection is crucial, and the practice uses multiple world‑leading imaging technologies to track GA changes over time.
1. Fundus Autofluorescence (FAF)
The ZEISS CLARUS 500 provides ultra‑widefield blue‑ and green‑autofluorescence imaging—essential for GA detection.
What Fundus Autofluorescence (FAF) reveals:
- Areas of RPE stress (hyper‑autofluorescence)
- Areas of cell loss (hypo‑autofluorescence)
- GA lesion borders and growth patterns
Peter Ivins Eye Care was the first practice in Scotland to adopt the CLARUS 500.
2. OCT (Optical Coherence Tomography)
With the ZEISS CIRRUS 6000, clinicians can visualise:
- Thinning of outer retinal layers
- Loss of photoreceptors
- RPE atrophy
- Early structural changes before symptoms develop
FastTrac eye‑tracking ensures crystal‑clear scans with minimal motion artefact. Click here to learn more about OCT Technology
3. OCT‑Angiography (OCT‑A)
OCT‑A maps blood flow and shows:
- Loss of choriocapillaris perfusion beneath GA
- Early detection of neovascular changes (wet AMD conversion)
4. Ultra‑widefield true‑colour imaging
The CLARUS 500 captures high‑definition colour images with exceptional clarity, making GA boundaries and drusen patterns easy to assess. Click here to learn more about Ultra-widefield true-colour ultra-high definition retinal imaging.
5. AI‑enhanced monitoring
Using ZEISS Retina Workplace and Altris AI, GA lesions are precisely mapped over time with automated measurements of:
- Atrophy area
- Growth rate
- New lesion formation
This level of monitoring allows patients to understand their condition and clinicians to make informed decisions about management and treatment.
Causes and Risk Factors for Geographic Atrophy
GA shares many of the same risk factors as dry AMD:
- Age (55+)
- Family history/genetics
- Smoking
- Low dietary antioxidants
- Cardiovascular disease
- Light exposure
- Low macular pigment density
Understanding these helps guide preventative recommendations.
What Is Valeda Photobiomodulation and How Can It Help GA?
The Lumithera Valeda Light Delivery System delivers specific wavelengths of therapeutic light designed to support retinal metabolism.
PBM uses:
- 590 nm yellow light – reduces inflammation
- 660 nm red light – boosts mitochondrial function
- 850 nm near‑infrared light – supports tissue repair
How PBM may help in geographic atrophy:
- Supports stressed RPE cells
- Enhances mitochondrial energy production
- Reduces oxidative stress
- Improves retinal metabolism
- May slow functional decline
While PBM is not a cure for GA, emerging research—including the LIGHTSITE trials—has shown improvements in visual function, contrast sensitivity, and patient‑reported outcomes. Many patients with GA also have earlier dry AMD changes in surrounding tissue—PBM may help support these stressed cells to function more effectively.
What Happens During Valeda PBM Therapy?
A typical Valeda session is:
- Quick (around 10 minutes)
- Completely non‑invasive
- Comfortable (no heat, no discomfort)
- Delivered in a series of sessions over several weeks
The headset delivers therapeutic light directly into the eyes while you sit comfortably. Most patients experience no side effects.
How Valeda Fits Into Advanced GA Care
At Peter Ivins Eye Care, PBM is part of a holistic GA management protocol that includes:
- High‑resolution structural imaging
- Functional vision assessment
- FAF mapping of atrophic areas
- OCT and OCT‑A monitoring
- Lifestyle and nutritional strategies
- Macular pigment enhancement programmes
- Home monitoring (Amsler grid)
PBM helps support surrounding retinal tissue, while imaging tracks lesion growth with unparalleled precision.
Who May Benefit from Valeda PBM?
Valeda may be appropriate for:
- Patients with soft drusen
- Early GA
- Intermediate AMD with high progression risk
- Patients with functional decline (contrast, reading)
- Those seeking a non‑invasive support option
- Patients unable to access emerging drug‑based GA treatments
A full GA and AMD evaluation determines suitability.
Why Choose Peter Ivins Eye Care for GA Management?
- Scotland’s first Valeda PBM clinic
- First in Scotland to use the ZEISS CLARUS 500
- CIRRUS 6000 OCT with unmatched resolution
- Integrated AI and multi‑modal imaging
- Led by Craig McArthur, an international AMD expert
- Multi‑award‑winning practice recognised for innovation and technology
Patients travel from across Scotland for the clinic’s expertise and technology.
Valeda treatment – Book Now
…we can help you understand your baseline, your risk, and your options.
📞 Call us: 0141 943 3300
📍 Visit our clinic in Bearsden, Glasgow
📅 Book a Valeda Assessment online
Learn more at www.valedascotland.co.uk
For more information about Valeda treatment visit: